 
- 积分
- 385
- 威望
- 385
- 包包
- 1381
|
Scientists have inserted mRNA into mesenchymal stem cells (MSCs) to produce a drug-delivery vehicle. Following systemic administration, the modified MSCs targeted and adhered to sites of inflammation, then released interleukin-10 that significantly reduced local swelling.% [7 {: [3 r* v" \! F) ^! a- G
8 ]+ ^/ V3 R, m+ }) y7 d
Historically, MSC-based treatments have had mixed results. MSCs exert their therapeutic effects in hit-and-run style. That is, MSCs are rapidly cleared after entering the bloodstream, typically within a few hours or days. Yet, despite the transience of MSC therapeutic action, a team of scientists reports that it has engineered MSCs that rapidly localized at a distant site of inflammation in an in vivo model, and delivered therapeutically relevant concentrations of the drug. The MSCs had been engineered enhanced homing and the expression of interleukin-10, which is not inherently produced by MSCs.9 n7 i; ~5 m/ K. T
" u+ d' w. a; b' S
The team of scientists included members representing Brigham and Women’s Hospital, the Harvard Stem Cell Institute, MIT, and Massachusetts General Hospital. The team, which published the results of its proof-of concept study in the October 3 issue of Blood, notes that its work is already drawing interest from biopharmaceutical companies.
, T- }" _$ \, K& g6 G2 ^* y/ U m: i
1 ~) Z: p2 q' ]$ G3 _7 r6 }“This opens the door to thinking of mRNA transfection of cell populations as next-generation therapeutics in the clinic, as they get around some of the delivery challenges that have been encountered with biological agents,” said Oren Levy, Ph.D., co-lead author of the study and instructor of medicine in the laboratory of research leader Jeffrey Karp, Ph.D. Dr. Karp, a Harvard Stem Cell Institute principal faculty member and associate professor at the Brigham and Women's Hospital, is also affiliated with Harvard Medical School and MIT.& q6 m* J2 `2 s0 g! @, w
1 {, C2 K X' X2 \5 o“If you think of a cell as a drug factory, what we’re doing is targeting cell-based, drug factories to damaged or diseased tissues, where the cells can produce drugs at high enough levels to have a therapeutic effect,” said Dr. Karp.: E" i* [8 B; H7 |0 d+ y" M1 U
9 U# u% k$ y! V/ s& P J# c9 ^
The key to success was the use of triple-transfected MSCs. In addition to expressing interleukin-1-, the cells expressed, in the team’s words, “functional rolling machinery.” This machinery consisted of P-selectin glycoprotein ligand-1(PSGL-1) and Sialyl-Lewisx (SLeX). Basically, the cells expressed both the immunomodulating agent and adhesive surface proteins.
9 n1 }' n3 s0 }; l( s; w" G |
-
总评分: 威望 + 2
包包 + 10
查看全部评分
|